Free Trial

BioSyent (CVE:RX) Stock Price Passes Below Fifty Day Moving Average - Time to Sell?

BioSyent logo with Medical background

BioSyent Inc. (CVE:RX - Get Free Report) shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$10.84 and traded as low as C$10.25. BioSyent shares last traded at C$10.26, with a volume of 1,000 shares changing hands.

BioSyent Trading Up 2.4 %

The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90. The business's 50 day moving average is C$10.79 and its 200-day moving average is C$11.07. The firm has a market cap of C$120.09 million, a P/E ratio of 17.04 and a beta of 0.93.

BioSyent Company Profile

(Get Free Report)

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

See Also

Should You Invest $1,000 in BioSyent Right Now?

Before you consider BioSyent, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.

While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Buy Early: 3 Tech Trends With Millionaire-Making Potential
5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines